Wickramasinghe Akurange Sujeevi Dammadinna, Attanayake Anoja Priyadarshani, Kalansuriya Pabasara, Menuka Arawwawala Liyanage Dona Ashanthi
Department of Pharmacy, Faculty of Health Sciences, The Open University of Sri Lanka, Colombo, Sri Lanka.
Department of Biochemistry, Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka.
Chem Biodivers. 2025 Jul;22(7):e202402965. doi: 10.1002/cbdv.202402965. Epub 2025 Mar 21.
Nanoencapsulation of herbal extracts is an emerging strategy in developing novel therapeutic agents to combat Type 2 diabetes mellitus. The present study aimed to investigate the sub-acute antidiabetic and antihyperlipidemic effects of aqueous ethanol 70% v/v extract of Murraya koenigii (L.) Spreng. (MAE) encapsulated gelatin nanoparticles (MGNP) using a high fat diet fed streptozotocin-induced Wistar rats with Type 2 diabetes mellitus. MGNP (10, 20, and 60 mg kg) and free MAE (85, 255, and 765 mg kg) were orally administered to rats for 28 days, biochemical and histopathological investigations were conducted. Rats treated with MGNP (therapeutic dose:20 mg kg) showed significant (p < 0.05) decrease in glycated hemoglobin (by 61.7%, 16.3%), homeostatic model assessment (HOMA) of insulin resistance (by 64.7%, 49.0%), triglyceride (by 49.2%, 10.4%), very low density lipoprotein-cholesterol (by 49.4%, 10.4%), tumor necrosis factor-alpha (by 75.9%, 41.5%), malondialdehyde (by 67.5%, 27.5%), and increased HOMA of β-cell function (by 949.5%, 449.7%), leptin (by 283.3%, 177.0%), catalase (by 429.8%, 102.9%), and total antioxidant capacity (by 688.0%, 13.4%) compared to diabetic control rats and MAE, respectively, indicating profound antihyperglycemic, antihyperlipidemic, anti-inflammatory, and antioxidant activities. The biochemical findings were corroborated by ameliorating histopathological abnormalities in the pancreas, proving that MGNP is a novel drug lead in pharmaceutical applications.
草药提取物的纳米封装是开发新型抗2型糖尿病治疗药物的一种新兴策略。本研究旨在使用高脂饮食喂养链脲佐菌素诱导的2型糖尿病Wistar大鼠，研究柯尼卡九里香（L.）Spreng. 70% v/v乙醇水提取物（MAE）封装的明胶纳米颗粒（MGNP）的亚急性抗糖尿病和抗高血脂作用。将MGNP（10、20和60毫克/千克）和游离MAE（85、255和765毫克/千克）口服给予大鼠28天，进行生化和组织病理学研究。与糖尿病对照大鼠和MAE相比，用MGNP（治疗剂量：20毫克/千克）治疗的大鼠糖化血红蛋白显著降低（分别降低61.7%、16.3%），胰岛素抵抗的稳态模型评估（HOMA）降低（分别降低64.7%、49.0%），甘油三酯降低（分别降低49.2%、10.4%），极低密度脂蛋白胆固醇降低（分别降低49.4%、10.4%），肿瘤坏死因子-α降低（分别降低75.9%、41.5%），丙二醛降低（分别降低67.5%、27.5%），β细胞功能的HOMA增加（分别增加949.5%、449.7%），瘦素增加（分别增加283.3%、177.0%），过氧化氢酶增加（分别增加429.8%、102.9%），总抗氧化能力增加（分别增加688.0%、13.4%），表明其具有显著的降血糖、降血脂、抗炎和抗氧化活性。胰腺组织病理学异常的改善证实了生化研究结果，证明MGNP是药物应用中的一种新型药物先导物。
